Scholarlink

Background <p>Tumour DNA methylation is a potentially valuable marker of breast cancer survival, but previous studies have been limited by relatively small sample sizes. This study aimed to use a large sample size to identify survival-associated DNA methylation markers and develop a methylation-based signature predictive of breast cancer survival.</p> Methods <p>We used DNA methylation data from 2,157 breast tumours collected in the Melbourne Collaborative Cohort Study (MCCS) and nine publicly available datasets. An epigenome-wide association study (EWAS) was conducted for five-year overall survival (<i>N</i> = 1,992 cases). Subgroup analyses were carried out by estrogen receptor status. Pathway enrichment analyses were conducted to identify related biological pathways. Elastic net Cox regression was used to develop a signature of survival from DNA methylation data and clinical characteristics, trained on publicly available datasets and tested in the MCCS (<i>N</i> = 425) in addition to the main clinical characteristics. A set of triple-negative tumours (<i>N</i> = 165) with disease-free survival as the outcome was used for additional replication.</p> Results <p>We identified 2,535 CpGs showing an association (<i>P </i>&lt; 1 × 10<sup>− 7</sup>) with survival in age-adjusted models, including 281 after adjustment for estrogen receptor (ER) status. In ER-positive tumours, there were 389 associations, of which 315 were absent from the primary EWAS. A 228-CpG signature showed a strong association with survival in the MCCS after adjustment for clinical characteristics: per SD, HR = 1.7, 95%CI: 1.2–2.3, <i>P</i> = 0.001, with a C-index of 0.79, compared with a C-index of 0.75 without methylation information (C-index increase: 0.04, 95%CI: 0.01–0.10). The signature was also predictive of disease-free survival beyond clinical characteristics in triple-negative tumours (HR per SD = 1.4, 95% CI: 1.1–1.8).</p> Conclusion <p>Our findings revealed numerous CpG sites where tumour DNA methylation was associated with breast cancer survival. A substantial improvement in the accuracy of five-year overall survival prediction was achieved by adding a 228-CpG epigenetic score to the main clinicopathological variables. These results suggest that DNA methylation markers may provide additional prognostic information beyond established clinicopathological factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Elaheh Zarean,
  • Shuai Li,
  • Enes Makalic,
  • Roger L. Milne,
  • Graham G. Giles,
  • Catriona McLean,
  • Melissa C. Southey,
  • Pierre-Antoine Dugué

摘要

Background

Tumour DNA methylation is a potentially valuable marker of breast cancer survival, but previous studies have been limited by relatively small sample sizes. This study aimed to use a large sample size to identify survival-associated DNA methylation markers and develop a methylation-based signature predictive of breast cancer survival.

Methods

We used DNA methylation data from 2,157 breast tumours collected in the Melbourne Collaborative Cohort Study (MCCS) and nine publicly available datasets. An epigenome-wide association study (EWAS) was conducted for five-year overall survival (N = 1,992 cases). Subgroup analyses were carried out by estrogen receptor status. Pathway enrichment analyses were conducted to identify related biological pathways. Elastic net Cox regression was used to develop a signature of survival from DNA methylation data and clinical characteristics, trained on publicly available datasets and tested in the MCCS (N = 425) in addition to the main clinical characteristics. A set of triple-negative tumours (N = 165) with disease-free survival as the outcome was used for additional replication.

Results

We identified 2,535 CpGs showing an association (P < 1 × 10− 7) with survival in age-adjusted models, including 281 after adjustment for estrogen receptor (ER) status. In ER-positive tumours, there were 389 associations, of which 315 were absent from the primary EWAS. A 228-CpG signature showed a strong association with survival in the MCCS after adjustment for clinical characteristics: per SD, HR = 1.7, 95%CI: 1.2–2.3, P = 0.001, with a C-index of 0.79, compared with a C-index of 0.75 without methylation information (C-index increase: 0.04, 95%CI: 0.01–0.10). The signature was also predictive of disease-free survival beyond clinical characteristics in triple-negative tumours (HR per SD = 1.4, 95% CI: 1.1–1.8).

Conclusion

Our findings revealed numerous CpG sites where tumour DNA methylation was associated with breast cancer survival. A substantial improvement in the accuracy of five-year overall survival prediction was achieved by adding a 228-CpG epigenetic score to the main clinicopathological variables. These results suggest that DNA methylation markers may provide additional prognostic information beyond established clinicopathological factors.